Head-To-Head Review: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Institutional & Insider Ownership

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Shuttle Pharmaceuticals and Tempest Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$9.15 million	($11.84)	-0.08
Tempest Therapeutics	N/A	N/A	-$41.84 million	($10.05)	-0.21

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Shuttle Pharmaceuticals and Tempest Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1	0	0	0	1.00
Tempest Therapeutics	1	2	0	0	1.67

Tempest Therapeutics has a consensus price target of $12.50, indicating a potential upside of 478.70%. Given Tempest Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Shuttle Pharmaceuticals.

Profitability

This table compares Shuttle Pharmaceuticals and Tempest Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-476.10%	-253.93%
Tempest Therapeutics	N/A	-310.89%	-125.12%

Risk & Volatility

Shuttle Pharmaceuticals has a beta of -0.82, meaning that its share price is 182% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.42, meaning that its share price is 342% less volatile than the S&P 500.

Summary

Tempest Therapeutics beats Shuttle Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.